Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 9%; BSE HEALTHCARE Index Down 0.2%
Mon, 9 Sep 9:28

Panacea Biotech Gains 9%; BSE HEALTHCARE Index Down 0.2%Image source: phive2015/www.istockphoto.com

Panacea Biotech share price has zoomed 9% and is presently trading at Rs 265.3.

Meanwhile, the BSE HEALTHCARE index is at 43,371.0 (down 0.2%).

Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 4.8%) and HIKAL CHEMIC (up 1.6%).

GRANULES INDIA (down 3.6%) and AJANTA PHARMA (down 2.6%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 136.9 to Rs 265.3, registering a gain of Rs 128.4 (up 93.8%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,163.1 to 43,371.0, registering a gain of 54.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 139.4%), Glenmark Pharma (up 116.4%) and GRANULES INDIA (up 112.9%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,059.0 (down 0.2%).

The top losers among the BSE Sensex today are Tata Steel (down 1.6%) and NTPC (down 1.4%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 24,813.7 (down 0.2%). ONGC and Tata Steel are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,780.3 to 81,059.0, registering a gain of 15,278.7 points (up 23.2%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -57.3.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 9%; BSE HEALTHCARE Index Down 0.2%". Click here!